Business
Alzheimer’s drug aducanumab faces major setback as US authorities consider whether to approve it – ABC News
A drug company is seeking to get an experimental Alzheimer’s drug approved by the FDA. If they succeed it would be a major breakthrough. But just how convincing…
For almost two decades, the field of Alzheimer’s research has been dogged by treatment failures, leaving patients and their families desperate for hope.
But the makers of a new experimental drug, currently under consideration for regulatory approval by the US Food and Drug Administration (FDA), want to change that.
If Aducanumab, developed by pharmaceutical company Biogen, is approved by the FDA, it would be the first Alzheimer’s drug to be greenlit in 20 years.
Last week, Biogen’s stock price soared…
-
Noosa News17 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business21 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General22 hours agoRush to buy homes before rate cuts send prices soaring
-
Business19 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025